HYALO 4 CONTROL CREAM 25 GM

Sodium Hyaluronate 0.2% + Silver Sulfadiazine 1%

Medical Description

Hyalo 4 Control Cream is a topical wound-care preparation combining sodium hyaluronate 0.2% with silver sulfadiazine 1%. The combination is designed to support wound healing while providing topical antimicrobial activity, particularly in wounds where protection against bacterial contamination or infection is clinically important.

Silver sulfadiazine 1% is a topical antimicrobial agent with established use as an adjunct in the prevention and treatment of wound sepsis associated with second- and third-degree burns. It provides broad antimicrobial activity against a range of organisms that may colonize burn wounds.

Sodium hyaluronate 0.2% is the sodium salt of hyaluronic acid, a naturally occurring component of the extracellular matrix. In topical wound preparations, it helps maintain a hydrated wound environment and may support cellular migration, granulation tissue formation and re-epithelialization—important processes in tissue repair.

Key Components

1. Sodium Hyaluronate 0.2%

• Helps maintain moisture within the wound bed.
• Supports the physiological wound-healing environment.
• May facilitate cellular migration and tissue regeneration.
• Has been investigated in acute and chronic wounds, including superficial burns and ulcers.

2. Silver Sulfadiazine 1%

• Topical antimicrobial belonging to the sulfonamide class.
• Helps prevent and treat microbial colonization/infection of susceptible burn wounds.
• Specifically established as an adjunctive treatment for second- and third-degree burns.

Potential Clinical Uses

Depending on the indication approved for the specific product and the clinician's assessment, this type of formulation may be used in the management of:

• Second- and third-degree burns, particularly where topical antimicrobial protection is required.
• Selected wounds at risk of bacterial contamination or infection.
• Wounds where maintaining a moist environment may support the healing process.
• Certain chronic or difficult-to-heal wounds under appropriate medical supervision.

Evidence concerning combinations of 0.2% sodium hyaluronate + 1% silver sulfadiazine has reported potential benefits in wound healing, including chronic pressure lesions; however, treatment should be selected according to wound type, depth, infection status and local clinical protocols.

How It Works

The two components provide complementary functions:

Silver sulfadiazine → antimicrobial protection
↓
Helps control susceptible microorganisms on the wound surface.

Sodium hyaluronate → wound-supportive environment
↓
Helps maintain hydration and supports processes involved in tissue repair and re-epithelialization.

Together, they provide antimicrobial wound protection plus support for the wound-healing environment.

Directions for Use

For products containing silver sulfadiazine 1%, standard prescribing information recommends that the wound be appropriately cleansed and, when necessary, debrided before application. Silver sulfadiazine cream is generally applied in a layer of approximately 1/16 inch (about 0.2 cm) once or twice daily, with reapplication when the treated area becomes uncovered.

Important: The exact frequency and duration of Hyalo 4 Control should follow the product's official instructions and the healthcare professional's recommendation, particularly for extensive, deep, infected or chronic wounds.

Important Precautions & Warnings

• For external/topical use only.
• Do not use in patients with known hypersensitivity to silver sulfadiazine, sulfonamides, or any component of the formulation.
• Silver sulfadiazine should generally not be used in premature infants or newborns during the first 2 months of life, and is contraindicated in women who are near term because of the potential risk of kernicterus.
• Use during pregnancy or breastfeeding should be determined by a healthcare professional according to the clinical situation.
• Caution is warranted in patients with G6PD deficiency, because hemolysis may occur in susceptible individuals.
• Large-area application, particularly over extensive burns, may increase systemic absorption; patients with extensive wounds may require medical monitoring.
• Silver sulfadiazine can occasionally cause local irritation, rash or hypersensitivity reactions. Rare but serious sulfonamide-associated reactions are possible.
• Prolonged use can be associated with fungal proliferation/superinfection, although clinically reported fungal superinfection is uncommon.
• Silver sulfadiazine may affect some topical enzymatic wound treatments because silver can inactivate certain enzymes.

When Medical Attention Is Needed

Seek prompt medical assessment for:

• Deep, extensive or circumferential burns.
• Burns involving the face, eyes, hands, feet, genital area or major joints.
• Increasing redness, swelling, warmth, pus, foul odor or worsening pain.
• Fever or other signs of systemic infection.
• Wounds that fail to improve or show progressive tissue damage.
• Any significant allergic reaction such as widespread rash, facial swelling or difficulty breathing.

The WHO emphasizes that significant burns require appropriate medical assessment and that topical medication should not replace proper burn-care management.

Storage

Store according to the manufacturer's instructions, keeping the tube tightly closed and protected from excessive heat and moisture. Keep out of the reach of children.

Patient Disclaimer

This information is provided for educational purposes only and does not replace professional medical advice, diagnosis or treatment. Hyalo 4 Control contains silver sulfadiazine, a medicinal antimicrobial agent, and should be used according to the product's official instructions or a healthcare professional's recommendation. The appropriate treatment depends on the type, depth, size and condition of the wound. Do not self-treat severe, deep or extensive burns. Seek urgent medical care when indicated. Always inform your doctor or pharmacist about allergies, pregnancy, breastfeeding, G6PD deficiency, kidney or liver problems, and other medicines or wound treatments you are using.

References

• U.S. National Library of Medicine / NIH – DailyMed: Silver sulfadiazine 1% prescribing information.
• NIH MedlinePlus: Silver Sulfadiazine Drug Information.
• World Health Organization (WHO): Burns – first aid and medical management information.
• PubMed/NIH: Research on hyaluronic acid and cutaneous wound healing.
• Cochrane/PMC: Review of dressings and topical agents containing hyaluronic acid for wound healing.
• Peer-reviewed wound-care literature: Evidence concerning sodium hyaluronate 0.2% combined with silver sulfadiazine 1%.